Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2014

01.08.2014

Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss

verfasst von: Nataliya Mar, Rebecca Kosowicz, Karen Hook

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

We report a case of a 36-year old patient with prior history of thrombosis in a setting of antiphospholipid antibody syndrome (APS) as well as pregnancy-associated catastrophic antiphospholipid syndrome (CAPS), resulting in multi-organ infarction and pregnancy loss. The episode of CAPS occurred while she was receiving antepartum low-dose aspirin and therapeutic-dose enoxaparin. This patient presented again at 6 weeks gestation and ultrasounds were consistent with fetal growth restriction, concerning for placental insufficiency and thrombosis. This time, hydroxychloroquine and monthly intravenous immunoglobulin (IVIG) infusions were added to her prophylaxis regimen, resulting in a successful delivery. Platelet count and antiphospholipid antibody titers were routinely monitored throughout pregnancy as markers of disease activity for APS. Current thromboprophylaxis guidelines do not address therapeutic options to prevent further pregnancy morbidity in women who develop recurrent episodes of thrombosis or CAPS despite receiving adequate anti-thrombotic treatment. Use of hydroxychloroquine and IVIG has been associated with good outcomes in this subset of patients.
Literatur
1.
Zurück zum Zitat Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346(10):752–763PubMedCrossRef Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. N Engl J Med 346(10):752–763PubMedCrossRef
2.
Zurück zum Zitat Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376(9751):1498–1509PubMedCrossRef Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376(9751):1498–1509PubMedCrossRef
3.
Zurück zum Zitat Kujovich J, Merrill PA (2011) Antiphospholipid antibodies and antithrombin deficiency: double trouble for pregnancy. Am J Hematol 86(12):1028–1031PubMedCrossRef Kujovich J, Merrill PA (2011) Antiphospholipid antibodies and antithrombin deficiency: double trouble for pregnancy. Am J Hematol 86(12):1028–1031PubMedCrossRef
4.
Zurück zum Zitat Di Prima FA, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E et al (2011) Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med 5(2):41–53PubMedCentralPubMed Di Prima FA, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E et al (2011) Antiphospholipid syndrome during pregnancy: the state of the art. J Prenat Med 5(2):41–53PubMedCentralPubMed
5.
Zurück zum Zitat Cervera R, Asherton RA (2006) Catastrophic antiphospholipid syndrome. Pathophysiol Haemost Thromb 35(1–2):181–186PubMedCrossRef Cervera R, Asherton RA (2006) Catastrophic antiphospholipid syndrome. Pathophysiol Haemost Thromb 35(1–2):181–186PubMedCrossRef
6.
Zurück zum Zitat Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12(7):530–534PubMedCrossRef Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12(7):530–534PubMedCrossRef
7.
Zurück zum Zitat Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP et al (2007) Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 66(6):740–746PubMedCentralPubMedCrossRef Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP et al (2007) Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 66(6):740–746PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736SPubMedCentralPubMed Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO (2012) Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736SPubMedCentralPubMed
9.
Zurück zum Zitat Hsiao GR, Wolf RE, Kimpel DL (2001) Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol 7(5):336–339PubMedCrossRef Hsiao GR, Wolf RE, Kimpel DL (2001) Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol 7(5):336–339PubMedCrossRef
10.
Zurück zum Zitat Sherer Y, Levy Y, Shoenfeld Y (2000) Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39(4):421–426CrossRef Sherer Y, Levy Y, Shoenfeld Y (2000) Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39(4):421–426CrossRef
11.
Zurück zum Zitat Xiao J, Xiong J, Zhu F, He L (2013) Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med 5(1):287–291PubMedCentralPubMed Xiao J, Xiong J, Zhu F, He L (2013) Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med 5(1):287–291PubMedCentralPubMed
12.
Zurück zum Zitat Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM et al (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182(1 Pt 1):122–127PubMedCrossRef Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM et al (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182(1 Pt 1):122–127PubMedCrossRef
13.
Zurück zum Zitat Sapir T, Blank M, Shoenfeld Y (2005) Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 1051:743–778PubMedCrossRef Sapir T, Blank M, Shoenfeld Y (2005) Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 1051:743–778PubMedCrossRef
14.
Zurück zum Zitat Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16PubMed Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16PubMed
15.
Zurück zum Zitat Diz-Kucukkaya R, Hancer VS, Artim-Esen B, Pekcelen Y, Inanc M (2010) The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis 29(3):303–309PubMedCrossRef Diz-Kucukkaya R, Hancer VS, Artim-Esen B, Pekcelen Y, Inanc M (2010) The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis 29(3):303–309PubMedCrossRef
16.
Zurück zum Zitat Bick RL (1994) Hypercoagulability and thrombosis. Med Clin North Am 78:635–665PubMed Bick RL (1994) Hypercoagulability and thrombosis. Med Clin North Am 78:635–665PubMed
17.
Zurück zum Zitat Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368(11):1033–1044PubMedCrossRef Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368(11):1033–1044PubMedCrossRef
18.
Zurück zum Zitat Ruffatti A, Tonello M, Del Ross T, Cavazzana A, Grava C, Noventa F et al (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96(3):337–341PubMed Ruffatti A, Tonello M, Del Ross T, Cavazzana A, Grava C, Noventa F et al (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96(3):337–341PubMed
20.
Zurück zum Zitat Cowchock FS, Reece EA, Baldan D et al (1992) Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 166:1318–1327PubMedCrossRef Cowchock FS, Reece EA, Baldan D et al (1992) Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 166:1318–1327PubMedCrossRef
21.
Zurück zum Zitat Noble LS, Kutteh WH, Lashey N et al (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 83:684–690PubMedCrossRef Noble LS, Kutteh WH, Lashey N et al (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 83:684–690PubMedCrossRef
22.
Zurück zum Zitat Stephenson MD, Ballem PJ, Tsang P et al (2004) Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 26:729–734PubMed Stephenson MD, Ballem PJ, Tsang P et al (2004) Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 26:729–734PubMed
23.
Zurück zum Zitat Kutteh WH, Ermel LD (1996) A clinical trial for the treatment of antiphospholipid-antibody associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 35:402–407PubMedCrossRef Kutteh WH, Ermel LD (1996) A clinical trial for the treatment of antiphospholipid-antibody associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 35:402–407PubMedCrossRef
24.
Zurück zum Zitat Rand JH, Wu XX, Quinn AS, Ashton AW, Chen PP, Hathcock JJ et al (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115(11):2292–2299PubMedCentralPubMedCrossRef Rand JH, Wu XX, Quinn AS, Ashton AW, Chen PP, Hathcock JJ et al (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115(11):2292–2299PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS et al (2003) Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12(7):524–529PubMedCrossRef Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS et al (2003) Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12(7):524–529PubMedCrossRef
26.
Zurück zum Zitat Pierangeli SS, Espinola R, Liu X, Harris EN, Salmon JE (2001) Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 44(4):876–883PubMedCrossRef Pierangeli SS, Espinola R, Liu X, Harris EN, Salmon JE (2001) Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 44(4):876–883PubMedCrossRef
27.
Zurück zum Zitat Duhem C, Dicato MA, Ries F (1994) Side-effects of intravenous immune globulins. Clin Exp Immunol 97(Suppl 1):79–83PubMedCentralPubMed Duhem C, Dicato MA, Ries F (1994) Side-effects of intravenous immune globulins. Clin Exp Immunol 97(Suppl 1):79–83PubMedCentralPubMed
28.
Zurück zum Zitat Uthman I, Godeau B, Taher A, Khamashta M (2008) The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 22(4):187–194PubMedCrossRef Uthman I, Godeau B, Taher A, Khamashta M (2008) The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 22(4):187–194PubMedCrossRef
29.
Zurück zum Zitat Persico M, Niglio A, Valentini G, Torella R (1996) Thrombocytopenia as a sensitive marker of immunologic activity in a patient with autoimmune chronic active hepatitis. Ital J Gastroenterol 28(6):340–342PubMed Persico M, Niglio A, Valentini G, Torella R (1996) Thrombocytopenia as a sensitive marker of immunologic activity in a patient with autoimmune chronic active hepatitis. Ital J Gastroenterol 28(6):340–342PubMed
30.
Zurück zum Zitat Zhao H, Li S, Yang R (2010) Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets 21(5):380–385PubMedCrossRef Zhao H, Li S, Yang R (2010) Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets 21(5):380–385PubMedCrossRef
31.
Zurück zum Zitat Spahr JE, Rodgers GM (2008) Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol 83(2):122–125PubMedCrossRef Spahr JE, Rodgers GM (2008) Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol 83(2):122–125PubMedCrossRef
Metadaten
Titel
Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss
verfasst von
Nataliya Mar
Rebecca Kosowicz
Karen Hook
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2014
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-014-1061-x

Weitere Artikel der Ausgabe 2/2014

Journal of Thrombosis and Thrombolysis 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.